Kestra Medical Technologies, Ltd. (KMTS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Jul 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KMTS SEC filings page.
Kestra Medical Technologies, Ltd. (KMTS) reported $95.1M in revenue for fiscal year 2026, up 59.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scaling is being outweighed by SG&A-led operating losses and financing-dependent cash use.
Gross margin expanded from1.3% in FY2024 to51.4% in FY2026, but operating profitability remained deeply negative. SG&A reached$164M against$95.1M of revenue, so gross-profit expansion was absorbed by overhead rather than converted into operating earnings.
Operating cash flow was
The current ratio declined from 6.7x in FY2025 to 4.4x in FY2026, indicating less short-term cushion even though current assets still exceeded current liabilities. Positive financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kestra Medical Technologies, Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kestra Medical Technologies, Ltd. held $262.2M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $81.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Kestra Medical Technologies, Ltd. scores 62/100 among other emerging companies.
Kestra Medical Technologies, Ltd. had 59M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Kestra Medical Technologies, Ltd. scores 1/100 among other emerging companies.
Kestra Medical Technologies, Ltd. spent $19.5M on research and development in fiscal year 2026, which was 8.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Kestra Medical Technologies, Ltd. scores 33/100 among other emerging companies.
Kestra Medical Technologies, Ltd. reported revenue of $95.1M in fiscal year 2026, against $59.8M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Kestra Medical Technologies, Ltd. scores 84/100 among other emerging companies.
Kestra Medical Technologies, Ltd.'s operations used $81.7M of cash in fiscal year 2026, against $77.6M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Kestra Medical Technologies, Ltd. scores 39/100 among other emerging companies.
Kestra Medical Technologies, Ltd.'s cash, cash equivalents and investments came to $262.2M at the end of fiscal year 2026, against $98.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Kestra Medical Technologies, Ltd. scores 80/100 among other emerging companies.
Kestra Medical Technologies, Ltd. scores 5.19, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.3B) relative to total liabilities ($98.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kestra Medical Technologies, Ltd. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Kestra Medical Technologies, Ltd. reported a net loss of $131.6M while operations used $81.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Kestra Medical Technologies, Ltd. reported an operating loss of $134.7M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kestra Medical Technologies, Ltd. generated $28.6M in revenue in Q4 2026. This represents an increase of 66.2% from the same quarter a year earlier. Against the prior quarter it is up 16.6%.
Kestra Medical Technologies, Ltd.'s EBITDA was -$37.0M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.2% from the same quarter a year earlier. Against the prior quarter it is down 12.9%.
Kestra Medical Technologies, Ltd. reported -$38.8M in net income in Q4 2026. This represents an increase of 25.4% from the same quarter a year earlier. Against the prior quarter it is down 13.7%.
Kestra Medical Technologies, Ltd. earned -$0.67 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 9.8%.
Cash & Balance Sheet
Kestra Medical Technologies, Ltd. recorded an outflow of $28.4M in free cash flow in Q4 2026, representing a cash shortfall after capex. This represents an increase of 9.7% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.
Kestra Medical Technologies, Ltd. held $99.7M in cash against $42.6M in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Margins & Returns
Kestra Medical Technologies, Ltd.'s gross margin was 54.8% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 10.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.
Kestra Medical Technologies, Ltd.'s ROE was -15.0% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is up 10.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Kestra Medical Technologies, Ltd. invested $5.6M in research and development in Q4 2026. This represents an increase of 4.6% from the same quarter a year earlier. Against the prior quarter it is up 13.3%.
Kestra Medical Technologies, Ltd. invested $9.7M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 30.8% from the same quarter a year earlier. Against the prior quarter it is down 1.4%.
Not reported for Q4 2026.
KMTS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.6M+66.2% | $24.6M+62.7% | $22.6M+53.4% | $19.4M+51.5% | $17.2M | $15.1M | $14.7M | $12.8M |
| Cost of Revenue | $13.0M+35.0% | $11.6M+36.3% | $11.1M+25.5% | $10.5M+22.6% | $9.6M | $8.5M | $8.9M | $8.6M |
| Gross Profit | $15.7M+105.5% | $12.9M+97.1% | $11.4M+96.0% | $8.9M+110.7% | $7.6M | $6.5M | $5.8M | $4.2M |
| R&D Expenses | $5.6M+4.6% | $5.0M+48.3% | $4.9M+39.0% | $4.0M+17.5% | $5.4M | $3.4M | $3.5M | $3.4M |
| SG&A Expenses | $49.4M-2.1% | $42.7M+79.4% | $38.3M+78.5% | $33.7M+75.4% | $50.5M | $23.8M | $21.5M | $19.2M |
| Operating Income | -$39.3M+18.4% | -$34.8M-68.8% | -$31.8M-66.0% | -$28.9M-56.7% | -$48.2M | -$20.6M | -$19.1M | -$18.4M |
| EBITDA | -$37.0M+20.2% | -$32.8M-75.2% | -$29.4M-70.2% | -$26.9M-67.2% | -$46.4M | -$18.7M | -$17.3M | -$16.1M |
| Interest Expense | $1.8M+4.8% | $1.9M+5.9% | $1.9M-18.0% | $1.9M+2.0% | $1.8M | $1.8M | $2.3M | $1.9M |
| Income Tax | $192K+88.2% | $35K+94.4% | $34K+325.0% | $33K+371.4% | $102K | $18K | $8K | $7K |
| Net Income | -$38.8M+25.4% | -$34.2M-58.8% | -$32.8M-61.0% | -$25.8M-29.9% | -$52.1M | -$21.5M | -$20.4M | -$19.9M |
| EPS (Basic) | -$0.67+57.3% | -$0.61+51.2% | -$0.64+46.2% | -$0.50+55.4% | -$1.57 | -$1.25 | -$1.19 | -$1.12 |
| EPS (Diluted) | -$0.67 | -$0.61 | -$0.64 | -$0.50 | -$1.57 | -$1.25 | -$1.19 | -$1.12 |
| Diluted Shares (Avg) | N/A | 56M | 51M | 51M | N/A | 20M | 20M | 20M |
KMTS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $358.5M+21.2% | $379.3M | $246.7M | $266.3M | $295.7M+543.6% | N/A | N/A | N/A |
| Current Assets | $222.4M-12.9% | $314.1M | $195.4M | $220.7M | $255.3M+1612.8% | N/A | N/A | N/A |
| Cash & Equivalents | $99.7M-58.0% | $291.3M+436.0% | $175.4M+128.1% | $201.2M+101.3% | $237.6M+2780.3% | $54.4M | $76.9M | $100.0M |
| Short-Term Investments | $96.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $65.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $98.8M+9.4% | $91.4M | $82.6M | $82.1M | $90.3M-64.6% | N/A | N/A | N/A |
| Current Liabilities | $50.4M+32.6% | $42.9M | $35.8M | $32.3M | $38.0M+15.2% | N/A | N/A | N/A |
| Non-Current Liabilities | $48.4M-7.5% | $48.4M | $46.9M | $49.9M | $52.4M-76.5% | N/A | N/A | N/A |
| Long-Term Debt | $42.6M+3.8% | $42.3M | $41.9M | $41.5M | $41.1M-3.4% | N/A | N/A | N/A |
| Total Equity | $259.7M+26.4% | $288.0M+211.7% | $164.1M+169.4% | $184.2M+185.1% | $205.4M+198.1% | -$257.9M | -$236.5M | -$216.5M |
| Retained Earnings | -$651.9M-25.3% | -$613.0M | -$578.9M | -$546.1M | -$520.2M-28.0% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
KMTS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.7M+22.2% | -$18.4M-2.1% | -$18.3M-1.6% | -$26.3M-50.1% | -$24.1M | -$18.0M | -$18.1M | -$17.5M |
| Depreciation & Amortization | $2.3M+26.6% | $2.0M+5.1% | $2.4M+26.9% | $2.0M-14.6% | $1.8M | $1.9M | $1.9M | $2.4M |
| Stock-Based Compensation | N/A | $10.1M+2102.2% | $8.7M+671.2% | $4.6M+1114.6% | N/A | $459K | $1.1M | $377K |
| Capital Expenditures | $9.7M+30.8% | $9.8M+141.1% | $7.3M+63.4% | $8.2M+16.0% | $7.4M | $4.1M | $4.4M | $7.0M |
| Free Cash Flow | -$28.4M+9.7% | -$28.2M-27.7% | -$25.6M-13.8% | -$34.4M-40.4% | -$31.4M | -$22.1M | -$22.5M | -$24.5M |
| Investing Cash Flow | -$172.7M-2232.6% | -$14.9M-235.3% | -$7.4M-67.9% | -$8.2M-17.0% | -$7.4M | -$4.5M | -$4.4M | -$7.0M |
| Financing Cash Flow | -$185K-100.1% | $149.2M+125463.0% | -$27K+95.3% | -$1.9M-101.6% | $214.7M | -$119K | -$575K | $116.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KMTS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.8%+10.5pp | 52.6%+9.2pp | 50.6%+11.0pp | 45.7%+12.8pp | 44.3% | 43.4% | 39.6% | 32.9% |
| Operating Margin | -137.4% | -141.6% | -140.7% | -149.1% | -279.8% | -136.5% | -130.1% | -144.2% |
| Net Margin | -135.6% | -139.2% | -145.3% | -133.3% | -302.1% | -142.5% | -138.5% | -155.6% |
| Return on Equity | -15.0%+10.4pp | -11.9% | -20.0% | -14.0% | -25.3% | N/A | N/A | N/A |
| Return on Assets | -10.8%+6.8pp | -9.0% | -13.3% | -9.7% | -17.6% | N/A | N/A | N/A |
| Current Ratio | 4.41-2.3x | 7.32 | 5.47 | 6.84 | 6.72+6.3x | N/A | N/A | N/A |
| Debt-to-Equity | 0.160.0x | 0.15 | 0.26 | 0.23 | 0.20 | N/A | N/A | N/A |
| Asset Turnover | 0.080.0x | 0.06 | 0.09 | 0.07 | 0.06 | N/A | N/A | N/A |
| FCF Margin | -99.1% | -114.7% | -113.5% | -177.8% | -182.5% | -146.2% | -153.0% | -192.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. KMTS | FY2026 | $95.1M | -$131.6M | N/A | $1.3B | 50/100 |
| Pulse Biosciences, Inc PLSE | FY2025 | $350K | -$72.8M | N/A | $3.8B | — |
| Embecta Corp. EMBC | FY2025 | $1.1B | $95.4M | 8.8% | $279.9M | 56/100 |
| Staar Surgical Co STAA | FY2025 | $239.4M | -$80.4M | -33.6% | $1.1B | 33/100 |
| BioLife Solutions Inc. BLFS | FY2025 | $96.2M | -$4.6M | -4.8% | $1.7B | 69/100 |
| AtriCure, Inc. ATRC | FY2025 | $534.5M | -$11.4M | -2.1% | $2.8B | 57/100 |
Where Kestra Medical Technologies, Ltd. Ranks
Frequently Asked Questions
What is Kestra Medical Technologies, Ltd.'s annual revenue?
Kestra Medical Technologies, Ltd. (KMTS) reported $95.1M in total revenue for fiscal year 2026. This represents a 59.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kestra Medical Technologies, Ltd.'s revenue growing?
Kestra Medical Technologies, Ltd. (KMTS) revenue grew by 59.0% year-over-year, from $59.8M to $95.1M in fiscal year 2026.
Is Kestra Medical Technologies, Ltd. profitable?
No, Kestra Medical Technologies, Ltd. (KMTS) reported a net income of -$131.6M in fiscal year 2026.
What is Kestra Medical Technologies, Ltd.'s EBITDA?
Kestra Medical Technologies, Ltd. (KMTS) had EBITDA of -$126.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Kestra Medical Technologies, Ltd. have?
As of fiscal year 2026, Kestra Medical Technologies, Ltd. (KMTS) had $99.7M in cash and equivalents against $42.6M in long-term debt.
What is Kestra Medical Technologies, Ltd.'s gross margin?
Kestra Medical Technologies, Ltd. (KMTS) had a gross margin of 51.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kestra Medical Technologies, Ltd.'s return on equity (ROE)?
Kestra Medical Technologies, Ltd. (KMTS) has a return on equity of -50.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Kestra Medical Technologies, Ltd.'s free cash flow?
Kestra Medical Technologies, Ltd. (KMTS) recorded an outflow of $116.6M in free cash flow during fiscal year 2026. This represents a -16.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kestra Medical Technologies, Ltd.'s operating cash flow?
Kestra Medical Technologies, Ltd. (KMTS) recorded an outflow of $81.7M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Kestra Medical Technologies, Ltd.'s total assets?
Kestra Medical Technologies, Ltd. (KMTS) had $358.5M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Kestra Medical Technologies, Ltd.'s capital expenditures?
Kestra Medical Technologies, Ltd. (KMTS) invested $34.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Kestra Medical Technologies, Ltd. spend on research and development?
Kestra Medical Technologies, Ltd. (KMTS) invested $19.5M in research and development during fiscal year 2026.
What is Kestra Medical Technologies, Ltd.'s current ratio?
Kestra Medical Technologies, Ltd. (KMTS) had a current ratio of 4.41 as of fiscal year 2026, which is generally considered healthy.
What is Kestra Medical Technologies, Ltd.'s debt-to-equity ratio?
Kestra Medical Technologies, Ltd. (KMTS) had a debt-to-equity ratio of 0.16 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kestra Medical Technologies, Ltd.'s return on assets (ROA)?
Kestra Medical Technologies, Ltd. (KMTS) had a return on assets of -36.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Kestra Medical Technologies, Ltd.'s P/E ratio?
Kestra Medical Technologies, Ltd. (KMTS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $1.3B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Kestra Medical Technologies, Ltd.'s price-to-sales ratio?
Kestra Medical Technologies, Ltd. (KMTS) trades at 14.1x sales, its market capitalization divided by revenue of $95.1M revenue, FY2026. The market capitalization is $1.3B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Kestra Medical Technologies, Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Kestra Medical Technologies, Ltd. (KMTS) held $262.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $81.7M over that year. Dividing the one by the other, the reported balance equals about 39 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Kestra Medical Technologies, Ltd.'s Altman Z-Score?
Kestra Medical Technologies, Ltd. (KMTS) has an Altman Z-Score of 5.19, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kestra Medical Technologies, Ltd.'s Piotroski F-Score?
Kestra Medical Technologies, Ltd. (KMTS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kestra Medical Technologies, Ltd.'s earnings high quality?
Kestra Medical Technologies, Ltd. (KMTS) reported a net loss of $131.6M while operations used $81.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kestra Medical Technologies, Ltd. cover its interest payments?
Kestra Medical Technologies, Ltd. (KMTS) reported an operating loss of $134.7M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Kestra Medical Technologies, Ltd.?
Kestra Medical Technologies, Ltd. (KMTS) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.